These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Current insights on the risk of thrombogenicity with off-label use of rFVlla. Key N Clin Adv Hematol Oncol; 2006 Jan; 4(1):34-5. PubMed ID: 16562367 [No Abstract] [Full Text] [Related]
6. Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe? Aledort LM J Thorac Cardiovasc Surg; 2003 Dec; 126(6):2112-3. PubMed ID: 14688750 [No Abstract] [Full Text] [Related]
7. Is there a high thrombosis rate associated with recombinant factor VIIa use in intractable hemorrhage in Australia? Dunkley S; Street A J Thromb Haemost; 2004 Oct; 2(10):1852-3. PubMed ID: 15456504 [No Abstract] [Full Text] [Related]
8. Safety profile of recombinant factor VIIa. Roberts HR; Monroe DM; Hoffman M Semin Hematol; 2004 Jan; 41(1 Suppl 1):101-8. PubMed ID: 14872430 [TBL] [Abstract][Full Text] [Related]
10. Recombinant activated factor VII: a new weapon in the fight against hemorrhage. Branch DW; Rodgers GM Obstet Gynecol; 2003 Jun; 101(6):1155-6. PubMed ID: 12798515 [No Abstract] [Full Text] [Related]
11. Recombinant factor VIIa and trauma: treatment that does not leave you in the cold. Levi M J Thromb Haemost; 2007 Feb; 5(2):242-3. PubMed ID: 17181827 [No Abstract] [Full Text] [Related]
12. Potential thrombogenic complications with the use of recombinant activated factor VII in combat trauma. Fareed J; Bick RL; Kessler C; Messmore HL; Rao G; Sasahara A; Haas S Clin Appl Thromb Hemost; 2007 Apr; 13(2):121-3. PubMed ID: 17456619 [No Abstract] [Full Text] [Related]
13. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Guillet B; Pinganaud C; Proulle V; Dreyfus M; Lambert T Thromb Haemost; 2002 Oct; 88(4):698-9. PubMed ID: 12362252 [No Abstract] [Full Text] [Related]
14. rFVIIa (Novoseven): the new panacea? Ickx BE Acta Anaesthesiol Belg; 2003; 54(4):333-5. PubMed ID: 14719355 [No Abstract] [Full Text] [Related]
15. Off-label use of recombinant factor VIIA concentrates after cardiac surgery. Despotis G; Avidan M; Lublin DM Ann Thorac Surg; 2005 Jul; 80(1):3-5. PubMed ID: 15975330 [No Abstract] [Full Text] [Related]
16. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. Bui JD; Despotis GD; Trulock EP; Patterson GA; Goodnough LT J Thorac Cardiovasc Surg; 2002 Oct; 124(4):852-4. PubMed ID: 12324751 [No Abstract] [Full Text] [Related]
17. Preemptive use of recombinant activated factor VII: many questions but few answers. Samama CM Can J Anaesth; 2006 Apr; 53(4):336-8. PubMed ID: 16575029 [No Abstract] [Full Text] [Related]
18. Rebuttal: accidental overdosage of recombinant factor VIIa due to mistaken package size: an inappropriate case report. Hermans CR; Deneys V Thromb Haemost; 2004 Dec; 92(6):1455-6; author reply 1456. PubMed ID: 15583757 [No Abstract] [Full Text] [Related]
19. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Cruz-Flores S Neurology; 2007 May; 68(20):1750-1; author reply 1751. PubMed ID: 17502566 [No Abstract] [Full Text] [Related]